SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (163)12/31/1998 2:29:00 PM
From: Lighthouse  Read Replies (1) of 666
 
Thanks for the response,

I thought the HAMA response was low as well. The press release on PIII did not go into much detail on that point: nasdaq.com {How is that for a URL}

However, while reading a clearly biased report from CS First Boston dated December 9, "as Coulter Pharmaceuticals pivotal results using Bexxar showed 34% HAMA response and 10-12% requirement of blood products casued by bone marrow damage." Author was Basu not Swartz.

I have been puzzled by the HAMA numbers posted by CSFB and have been unable to corroberate (sp?) them. Like you I felt the HAMA response was under 10%, but I could be wrong. CSFB has been IDPH's banker before, so their stuff needs to be filtered.

Your eventual sales figures for Bexxar are slightly higher than mine, and I believe your discount rate on future earnings is lower than mine as well. All said CLTR looks a lot better than IDPH here.

Cheers,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News